Importantly, we have identified novel pathways containing histone H2A and H2B genes as a mechanism of drug resistance across a spectrum of breast cancer cell lines and validated this finding in the BR9601 adjuvant clinical trial cohort. Here, H2BC21 is linked to breast carcinoma.